A Rothe, H Schulz, T Elter, A Engert, M Reiser. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin’s lymphoma. Haematologica 2004;89(7):875-876; https://doi.org/10.3324/%x.